Search

Read about an FDA approval for immunotherapy to treat head and neck squamous cell carcinoma.

… Wednesday, October 1, 2025 People with locally advanced  head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The  U.S. Food and Drug Administration (FDA) has approved the immunotherapy drug  pembrolizumab (Keytruda® ) to

The June 29 edition of “MSK Science Spotlight” will feature chemical biologist Yael David, PhD, “Uncovering Epigenetic Events that Drive Oncogenesis.

… Monday, June 29, 2020 The June 29 edition of “ MSK Science Spotlight ” will feature chemical biologist Yael David, PhD, “Uncovering Epigenetic Events that Drive Oncogenesis.” A member of Sloan Kettering Institute , Dr. David develops and applies methods in chemical biology toward studying epigenetic

At Memorial Sloan Kettering Cancer Center’s 45th annual ceremony, graduating master's and PhD students were honored and award winners were recognized.

… Friday, May 17, 2024 GSK master’s degree recipients with members of the platform party GSK master’s degree recipients with members of the platform party. Back row, from left: Dr. Urvi Ajay Shah, Dr. Michael Scordo, Dr. Ioannis Politikos, Dr. Ivan Sergueivich Kotchetkov, and Dr. Vance Broach. Front row

Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI).

… Friday, November 17, 2017 Summary Zeda Zhang was recently honored with an award from the NCI for his work addressing drug resistance in prostate cancer care. Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI). The nationally

Genetic sequencing of prostate tumors can identify men who should receive immunotherapy drugs.

… Friday, January 11, 2019 Summary Immunotherapy drugs called checkpoint inhibitors can be very effective but don’t work for most people with prostate cancer . A small subset of men whose prostate tumors have a genetic abnormality called high microsatellite instability do respond to the drugs. Genetic

… Tuesday, August 21, 2012 Summary A team of researchers has made a breakthrough in solving a problem that has defied biologists for decades: How to compute a protein’s three-dimensional structure, or shape, based on genetic information. The discovery could accelerate diverse areas of biomedical discovery

This form of cell death is called ferroptosis, and certain cancer cells are especially vulnerable to it.

… Tuesday, August 27, 2019 Summary The same properties that make certain cancers hard to treat may also promote their death by ferroptosis, scientists at the Sloan Kettering Institute have found. Cells can die in several ways. One such method, discovered only within the past decade, is ferroptosis — literally

In a recently published paper MSK's Jun Mao explores the global challenges of cancer control and the current status of integrative oncology, offering recommendations to improve access to safe, effective, evidence-based, and culturally sensitive cancer care.

… Thursday, November 18, 2021 Cancer is a global health challenge that impacts countries large and small, affluent and impoverished. With population growth and aging, and success in the management of other acute and chronic diseases, the number of new cancer cases is expected to rise over the next two

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Thursday, April 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Katharine Hsu Named Director of Tri-Institutional MD-PhD Program Katharine Hsu MSK’s Katharine Hsu, MD, PhD , has been named director of the Tri-Institutional MD-PhD Program , a joint

A novel treatment for prostate cancer involves a light-sensitive drug that destroys small tumors and the blood vessels that feed them.

… Monday, September 18, 2017 Summary Treatment of prostate cancer involves the risk of complications that can reduce quality of life. MSK researchers are exploring a new technology called vascular-targeted photodynamic therapy to help alleviate this risk. It can destroy small prostate tumors with a drug